These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 9781721)

  • 1. Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis--a randomized, clinical trial.
    Clark MA; Plank LD; Connolly AB; Streat SJ; Hill AA; Gupta R; Monk DN; Shenkin A; Hill GL
    Crit Care Med; 1998 Oct; 26(10):1650-9. PubMed ID: 9781721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.
    Reinhart K; Wiegand-Löhnert C; Grimminger F; Kaul M; Withington S; Treacher D; Eckart J; Willatts S; Bouza C; Krausch D; Stockenhuber F; Eiselstein J; Daum L; Kempeni J
    Crit Care Med; 1996 May; 24(5):733-42. PubMed ID: 8706447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.
    Abraham E; Wunderink R; Silverman H; Perl TM; Nasraway S; Levy H; Bone R; Wenzel RP; Balk R; Allred R
    JAMA; 1995 Mar 22-29; 273(12):934-41. PubMed ID: 7884952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group.
    Dhainaut JF; Vincent JL; Richard C; Lejeune P; Martin C; Fierobe L; Stephens S; Ney UM; Sopwith M
    Crit Care Med; 1995 Sep; 23(9):1461-9. PubMed ID: 7664546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The organ protective effects and timing of continuous blood purification in the treatment of severe sepsis：a double-blind randomized controlled trial].
    Zhou R; Weng F; Dai W; Yan J
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2016 Mar; 28(3):241-5. PubMed ID: 29917338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.
    Abraham E; Glauser MP; Butler T; Garbino J; Gelmont D; Laterre PF; Kudsk K; Bruining HA; Otto C; Tobin E; Zwingelstein C; Lesslauer W; Leighton A
    JAMA; 1997 May; 277(19):1531-8. PubMed ID: 9153367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis.
    Vincent JL; Spapen H; Bakker J; Webster NR; Curtis L
    Crit Care Med; 2000 Mar; 28(3):638-42. PubMed ID: 10752807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical study on continuous plasma filtration absorption treatment for burn sepsis].
    Meng A; Ren Y; Yang L; He L; Zeng S; Liu Q
    Zhonghua Shao Shang Za Zhi; 2014 Aug; 30(4):310-4. PubMed ID: 25429809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Components of energy expenditure in patients with severe sepsis and major trauma: a basis for clinical care.
    Uehara M; Plank LD; Hill GL
    Crit Care Med; 1999 Jul; 27(7):1295-302. PubMed ID: 10446823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial.
    Lauterbach R; Pawlik D; Kowalczyk D; Ksycínski W; Helwich E; Zembala M
    Crit Care Med; 1999 Apr; 27(4):807-14. PubMed ID: 10321674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: results from a double-blind, randomized, placebo-controlled study.
    Zeni F; Pain P; Vindimian M; Gay JP; Gery P; Bertrand M; Page Y; Page D; Vermesch R; Bertrand JC
    Crit Care Med; 1996 Feb; 24(2):207-14. PubMed ID: 8605790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma cytokine measurements augment prognostic scores as indicators of outcome in patients with severe sepsis.
    Oberholzer A; Souza SM; Tschoeke SK; Oberholzer C; Abouhamze A; Pribble JP; Moldawer LL
    Shock; 2005 Jun; 23(6):488-93. PubMed ID: 15897799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does N-acetyl-L-cysteine influence cytokine response during early human septic shock?
    Spapen H; Zhang H; Demanet C; Vleminckx W; Vincent JL; Huyghens L
    Chest; 1998 Jun; 113(6):1616-24. PubMed ID: 9631802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD14 receptor occupancy in severe sepsis: results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14).
    Reinhart K; Glück T; Ligtenberg J; Tschaikowsky K; Bruining A; Bakker J; Opal S; Moldawer LL; Axtelle T; Turner T; Souza S; Pribble J
    Crit Care Med; 2004 May; 32(5):1100-8. PubMed ID: 15190957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group.
    Fisher CJ; Opal SM; Dhainaut JF; Stephens S; Zimmerman JL; Nightingale P; Harris SJ; Schein RM; Panacek EA; Vincent JL
    Crit Care Med; 1993 Mar; 21(3):318-27. PubMed ID: 8440099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma proinflammatory cytokine concentrations, Acute Physiology and Chronic Health Evaluation (APACHE) III scores and survival in patients in an intensive care unit.
    Friedland JS; Porter JC; Daryanani S; Bland JM; Screaton NJ; Vesely MJ; Griffin GE; Bennett ED; Remick DG
    Crit Care Med; 1996 Nov; 24(11):1775-81. PubMed ID: 8917024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationships between plasma cytokine concentrations and leukocyte functional antigen expression in patients with sepsis.
    Lin RY; Astiz ME; Saxon JC; Saha DC; Rackow EC
    Crit Care Med; 1994 Oct; 22(10):1595-602. PubMed ID: 7924371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of endotoxin release and cytokine production induced by antibiotics in patients with Gram-negative nosocomial pneumonia.
    Maskin B; Fontán PA; Spinedi EG; Gammella D; Badolati A
    Crit Care Med; 2002 Feb; 30(2):349-54. PubMed ID: 11889308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis.
    Rice TW; Wheeler AP; Morris PE; Paz HL; Russell JA; Edens TR; Bernard GR
    Crit Care Med; 2006 Sep; 34(9):2271-81. PubMed ID: 16810105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unopposed interleukin-1 is necessary for increased plasma cytokine and eicosanoid levels to develop in severe sepsis.
    Slotman GJ; Quinn JV; Wry PC; Brathwaite CE; Friedman BM
    Ann Surg; 1997 Jul; 226(1):77-84. PubMed ID: 9242341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.